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Summary
Rituximab is an effective treatment of rheumatoid arthritis
(RA), which has been approved for the treatment of mod-
erate to severe disease in patients with an inadequate re-
sponse to anti-TNF therapies. Rituximab differs from other
available biological agents for RA by way of its unique
mode of action and unrivalled long dosing interval. The ef-
ficacy of rituximab subsides progressively over time and
re-therapy is generally required to maintain long term dis-
ease control. The timing of re-treatment is currently not
well established and varies widely in clinical practice. The
present document is a concise recommendation regarding
re-treatment with rituximab, based on validated outcomes
such as the DAS28 and the EULAR response criteria. The
recommendation was established through consensus
between practitioners familiar with rituximab therapy in
RA. Optimisation of the rituximab re-treatment schedule
may improve patient outcomes and balance risks and bene-
fits for the individual patient.
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Introduction
Rituximab has been approved in Switzerland since 2006, in
combination with methotrexate, for the treatment of mod-
erate to severe active rheumatoid arthritis (RA) in patients
with an inadequate response to anti-TNF therapies.
In clinical trials as well as in daily practice, rituximab
has proven to be efficacious by improving clinical signs
and symptoms as well as physical function and quality-
of-life parameters [1–4]. In addition, 2 years’ X-ray data
have clearly shown that rituximab reduces the rate of radio-
graphic progression and inhibits joint damage [5, 6].
Finally, published data from clinical trials and follow-
up studies confirm the good safety profile of rituximab,
with data from more than 3000 patients with up to five
treatment cycles not showing any increase in severe ad-
verse events, infections or malignancies over time and/or
with cycle number [7, 8].
Rituximab clearly differentiates itself from the other
biological therapies for RA by its unique mode of action
and unrivalled long dosing interval. While the long dura-
tion of response makes rituximab an attractive therapeutic
option for RA patients, its effect decreases with time and
re-therapy with rituximab is an essential part of a long term
successful disease control.
Data from Switzerland, extracted from the SCQM-RA
database, indicate a trend in the pattern of re-treatment with
a shortening of the mean re-treatment interval from 11.9
months in 2006 to 9.4 and 7.8 months in 2007 and 2008 re-
spectively [9]. However, optimal timing of re-treatment re-
mains a matter of discussion.
Supporters of longer re-treatment intervals stress the
higher convenience for patients, the lower costs and a po-
tentially better safety, while supporters of early re-treat-
ment and thus shorter and fixed re-treatment intervals em-
phasise improved and sustained efficacy.
Scope and purpose
The present document is intended to complement the inter-
national Consensus Statement on the use of rituximab in
patients with RA published by Josef Smolen and his co-
authors from the Working Group on the Rituximab Con-
sensus Statement in 2007 [10], as there is a need for concise
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and usable guidelines regarding re-treatment with rituxim-
ab. Rheumatologists from the Swiss University Hospitals
reviewed published data supporting different strategies of
re-treatment and pooled their own experience and clinic-
al practice in an effort to create such a consensus docu-
ment specifically on rituximab re-treatment. The document
is intended to improve and standardise the current practice
in Switzerland using a pragmatic approach. This consensus
is also endorsed by the clinical affairs group of the Swiss
Society of Rheumatology (SSR/SGR) and the key prin-
ciples on re-treatment will be incorporated into the SSR/
SGR treatment guideline on rituximab. It can easily be as-
sumed that any such recommendation is going to evolve
over time as experience is gained and more information
becomes available, e.g., on markers and predictors of re-
sponse.
Aspects on the initial response to
Rituximab and timing of re-treatment
Individual versus fixed re-treatment
There is a large inter-individual variability in the duration
of response to rituximab, a fact that makes it difficult to op-
timally time re-treatment. In principle there are two differ-
ent options:
Individual re-treatment intervals, often referred to as
“treatment on demand” and as recommended by Smolen et
al. [10] are difficult to manage as no predictor of relapse is
currently available. Too long intervals between two cycles
of rituximab therapy imply the risk of relapses, a decrease
of quality of life and potentially irreversible joint damage.
The authors agreed that, in current practice, many patients
still experience too large treatment intervals with evidence
of flares at time of re-treatment [9].
Fixed and short re-treatment intervals would mitigate
this risk of flare-ups and even potentially increase efficacy.
However, fixed and short re-treatment intervals for all pa-
tients would decrease the convenience and cost saving of
longer intervals, as well as potentially mitigate the capacity
of the immune system to renew B-cells after repeated de-
pletion. While concern about long-term safety is always le-
gitimate, there is at present no data to substantiate a safety
risk.
Data on re-treatment strategies remain scarce. More
recent and post-launch clinical trials conducted by F.
Hoffmann-La Roche AG and Genentech Ltd set out for
Figure 1
EULAR response criteria.
fixed 6-month re-treatment intervals. A study specifically
designed to check the effect of re-treatment on disease
activity demonstrated that two courses of rituximab ap-
proximately 6 months apart resulted in improved and sus-
tained efficacy at one year, as compared with a single
course per year. Differences in efficacy between both
groups were first observed following weeks 28 to 32, and
patients receiving only one cycle per year had a two- to
fourfold higher risk to loose their initial response (i.e.,
ACR 20 / 50 or 70). Furthermore, the safety profile of both
study groups was comparable, in particular with respect to
serious adverse events and severe infections [11].
When seeking to balance risk and benefit of different
re-treatment strategies for the patient, multiple factors
come into play, from treatment-related factors to patient-
physician interaction-related factors. Clearly, the medica-
tion needs to be tailored to an individual’s need; this docu-
ment aims to help the practitioner in his decision.
Disease activity evaluation
Disease activity and its evaluation remains a challenging
concept. This recommendation uses the DAS28 index as a
tool to simplify implementation of a standardised re-treat-
ment strategy. DAS28 includes assessment of swollen and
tender joints, pain and CRP or ESR. Its use allows defining
the degree of disease activity as well as response to treat-
ment (EULAR response criteria, fig. 1) [12]. However, the
clinician should keep its limitations in mind, and individu-
al components of the DAS28 as well as other symptoms of
disease activity such as fatigue have also to be evaluated
for concordance with the DAS28 value and the EULAR re-
sponse.
The authors further advocate yearly x-rays of hands and
feet to evaluate radiological progression. However, radiolo-
gical data is not considered to prevail over disease activity.
Hence treatment should not be pursued in the absence of
clinical response.
Finally, determination of anti-CCP and rheumatoid
factor (RF) is certainly most useful before starting ritux-
imab therapy, as higher probability of response is obtained
in seropositive patients [13]. However, there is no unequi-
vocal evidence that repeated testing of auto-antibodies will
help to optimise re-treatment.
Potential future development
Rituximab usually leads to rapid B-cell depletion. There is
also a certain association between loss of response and re-
turn of B cells [14], but analytical techniques need to be re-
fined and further validated before any monitoring of B cells
or other parameters can be broadly applied for scheduling
re-treatment in individual patients.
Persistent or re-emerging inflammatory activity in the
synovium can be displayed by joint B-mode ultrasound
[15] and the use of ultrasound may also be helpful in dif-
ficult cases to decide on re-treatment. However, as for B
cell markers, its role in clinical practice needs to be further
defined by studies and confirmed by validation for this spe-
cific purpose.
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Risk of Progressive Multifocal Leukoencephalopathy
(PML)
Despite recent publications regarding a new case of PML in
an RA patient treated with rituximab [16], the authors be-
lieve that, considering the rarity of the cases and the lack
of causal relationship with repeated courses of rituxim-
ab, the present recommendation remains valid until further
data become available, in particular in an TNF-inadequate
responders’ population. However, physicians should con-
sider this diagnosis in the presence of neurological symp-
toms.
Recommendations
Categories of response
Considerations regarding re-treatment depend on the ob-
served response to rituximab treatment which can be cat-
egorised into 3 different outcomes based on DAS28 and
EULAR response rates:
1. no response or no significant response
2. definite response with significant residual disease
activity
3. definite response with low or minimal disease activity
The authors recommend that response to rituximab treat-
ment be evaluated between 3 to 4 months after the initial
infusion. After this time point it becomes unlikely that pa-
tients with no response will experience a significant de-
crease in disease activity. These patients should therefore
be managed further as outlined below for “non-respon-
ders”.
For patients with definite response at 3 to 4 months, the
degree of response should be re-evaluated at a further time
point around 6 months, when decision about re-treatment is
going to be taken according to the above response categor-
ies.
Re-treatment strategy differs for the 3 above mentioned
categories of initial response to rituximab as summarised in
table 1 and as further explained below:
Non-responders
These patients do not show any significant change in dis-
ease activity upon the first rituximab treatment (non-re-
sponse as defined by the EULAR criteria, fig. 1).
There is no objective evidence to support that these pa-
tients should receive an additional course of rituximab if
therapeutic alternatives are available [17].
For the rare patient with no alternatives, it could be
reasonable to envisage a second course of rituximab, some
data having shown occasional benefit of re-treatment in
this non-responder population [18].
Responders with residual disease activity
These patients experience a distinct response to rituximab,
usually described as moderate response according to
EULAR criteria. However, they did not achieve low or
minimal disease activity at the 6-month time point. These
patients have persistent disease activity that will lead to
progressive joint destruction and disability.
In accordance with the prevailing treatment paradigm
in RA [19, 20] according to which remission is the aim,
these patients’ treatment should be optimised without delay
and re-treatment used to further lower disease activity and
avoid flares. These patients should be re-treated at the earli-
est studied time point, which is around 6 months after the
previous cycle of rituximab.
Published data have shown that repeated courses of
rituximab increase the efficacy relative to original baseline
and were well tolerated [3, 4, 21]. In rituximab responders,
two courses of rituximab approximately 6 months apart
resulted in a significantly improved efficacy at one year as
compared with a single course within the same year, and
this with a comparable safety profile [11]. Furthermore, the
latest evaluation of SCQM-RA data confirms that the mean
disease activity starts to rise again 6 months after a treat-
ment course [9, 22].
As the effect of rituximab re-treatment is not immediate
and needs approximately 2 months to fully develop, there
is no reason to delay re-treatment beyond 6 months as this
patient group still has active disease. Finally, as remission
should be achieved as fast as possible, adequate use of con-
comitant DMARD or glucocorticoid treatment (e.g., intra-
articular or bridging glucocorticoids) should be considered,
as well as alternative biologic treatment strategies if the de-
sired treatment success has not been reached with repeated
courses.
Optimal responders: patients with low disease activity
These patients experienced a major response with low or
minimal residual disease activity following a treatment
cycle of two infusions of rituximab, which pragmatically is
best described as a DAS28 <3.2 or even <2.6. To qualify
for this patient category, a response should already be ob-
vious at 3 to 4 months after treatment and should be main-
tained or improved at 6 months.
In this category, optimal timing of re-treatment remains
a matter of discussion between the advocates of longer in-
tervals and those in favour of shorter and fixed re-treatment
intervals. The majority of the authors of this document
would rather adopt a “wait and see” strategy, accepting
some gap of optimal disease control against the potential
harm due to multiple repeated courses, while the minor-
ity would favour a fixed 6-months re-treatment protocol for
this patient category as well or at least a very aggressive
“wait and see” strategy in the hope to optimise efficacy
over risks.
In any case, but in particular with a “wait and see”
strategy, regular monitoring visits are mandatory to detect
signs of disease flare-up. The rheumatologist should check
for swollen and tender joints, and other clinical signs and
symptoms or lab parameters (ESR or CRP) that would in-
dicate disease reactivation. Additionally, the patient should
be thoroughly educated to contact his physician as soon as
the first symptom of flare-up arises. For a well-educated
patient, quarterly visits may be appropriate; else, more reg-
ular visits should be planned.
An increase in DAS28 as well as any other sign of dis-
ease activity should trigger re-treatment. A prompt re-treat-
ment of any patient experiencing even mild symptoms of
increasing disease activity would provide the best chance
to remain in low disease activity state or remission. Only a
very minor proportion of patients will remain in rituximab-
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induced remission for more than one year. The authors feel
that re-treatment usually should not be delayed beyond one
year with annual x-rays to make sure that the disease is
not erosive despite low disease activity. Any observation
of progressive joint damage or inflammatory activity in the
synovium would deserve a more aggressive approach.
Dosage
Until further data become available, the authors recom-
mend a dosage of 2×1000 mg for re-treatment as approved
by the health authorities, especially as the use of 2×500 mg
per cycle did not seem to demonstrate a similar benefit on
structural damage in the ongoing IMAGE study [23].
Conclusion
Rituximab has proven to be efficacious in the treatment of
RA. Despite its long duration of response, re-treatment re-
mains an essential part of a successful therapy. In practice,
many patients on rituximab experience flare-ups as treat-
ment intervals are too long. Optimal treatment intervals re-
main a matter of discussion. This document aims to im-
prove and standardise the current practice in Switzerland
using a pragmatic approach. It is suggested that disease
evaluation be based on DAS28 and EULAR response cri-
teria while also considering quality of life criteria and ra-
diographic progression. Three categories of response have
been defined requiring a different strategy of re-treatment
1. Non-responder patients not achieving at least moderate
EULAR response would not receive rituximab re-
treatment if other therapeutic options are available.
2. Responders with remaining residual disease activity
should generally be retreated after 6 months to
maintain and improve response.
3. Patients achieving low or minimal disease activity are
considered optimal responders. The majority of the
authors recommend a “wait and see” strategy with
treatment intervals that rarely exceed 12 months.
Patients should be trained to see the doctor upon first
signs of relapse. Erosive disease should be treated
more aggressively to avoid irreversible joint damage.
Optimisation of re-treatment means balancing risk and be-
nefit for the patient and some rheumatologists will favor a
more cautious approach than others. Tailoring of individual
treatments is necessary, and this document aims to help the
practitioner in this difficult decision until markers and pre-
dictors of response and relapse become available.
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